PT-141 Side Effects: What Studies Report

PT-141 is the development code for bremelanotide, a melanocortin receptor agonist derived from the melanocyte-stimulating hormone family. The early human literature on it consists mainly of small, industry-run safety and pharmacology studies in men, plus later review articles that place the peptide alongside other agents studied for sexual and metabolic indications. This page summarises what those publications reported about adverse events, tolerability and study design, and it separates that evidence from the handling and refrigeration questions that the published abstracts simply do not address. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication or peptide.

How PT-141 Was Studied in Humans

Two 2004 reports in the International Journal of Impotence Research established the first human safety picture. One evaluated the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141 in healthy male subjects and in patients with an inadequate response to sildenafil (PMID 14999221). The companion paper was a double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141 in healthy males and in patients with mild-to-moderate erectile dysfunction (PMID 14963471). A 2005 Urology study then examined co-administration of low doses of intranasal PT-141 with sildenafil in men with erectile dysfunction and reported an enhanced erectile response compared with the components alone (PMID 15833522).

Because these were dose-ranging pharmacology studies rather than long-term treatment trials, the safety information they generated describes short exposure windows in small, screened male populations. Researchers monitored vital signs, laboratory values and reported symptoms over hours to days rather than months. That design context matters when interpreting any adverse-event list: it tells readers what was measured, not what happens with repeated or unsupervised use.

More recent syntheses add breadth rather than new safety data. A 2025 narrative review in Expert Opinion on Pharmacotherapy surveyed peptides and amino acids studied for erectile dysfunction, including current applications and future directions, and discussed melanocortin-pathway agents within that landscape (PMID 40069591). A 2026 review in the International Journal of Molecular Sciences covered therapeutic peptides in aesthetic, metabolic and endocrine conditions and summarised effects, safety and clinical applications across that class (PMID 42123471).

PT-141 Side Effects: What Studies Report

Nausea, flushing and headache

The most consistently described complaints in the human work are gastrointestinal and vasomotor. In the subcutaneous safety and pharmacokinetic study, researchers reported nausea, flushing and headache among the adverse events observed, with a dose-related pattern across the escalating single-dose groups (PMID 14999221). The placebo-controlled intranasal study was likewise structured to capture treatment-emergent adverse events alongside pharmacokinetic sampling, and its authors characterised tolerability at the doses examined (PMID 14963471). Reviews of the broader therapeutic-peptide class have described nausea and flushing as recurring tolerability issues for melanocortin-receptor agents (PMID 42123471).

Cardiovascular measurements

Blood pressure and heart rate were part of the monitored endpoints in the early pharmacology studies, since melanocortin signalling influences autonomic tone; the subcutaneous study reported on safety and pharmacodynamic measures collected in healthy men and in sildenafil non-responders (PMID 14999221). The 2025 narrative review discussed cardiovascular considerations as part of its appraisal of peptide approaches to erectile dysfunction and noted that safety characterisation remains a limiting factor for several agents (PMID 40069591).

Route-specific observations

Adverse events in the intranasal programme were reported for a nasal spray formulation in healthy males and men with mild-to-moderate erectile dysfunction, a route that introduces local upper-airway complaints not relevant to injection (PMID 14963471). The subcutaneous study, by contrast, assessed a formulation delivered beneath the skin and reported on its pharmacokinetics and tolerability in the same two population types (PMID 14999221). Comparisons between routes are therefore indirect: the doses, formulations and absorption profiles differed.

Combination with a PDE5 inhibitor

The 2005 Urology report examined low doses of intranasal PT-141 given together with sildenafil and described an enhanced erectile response in men with erectile dysfunction (PMID 15833522). Because both agents affect vascular tone, combination studies are the setting in which blood-pressure interactions are most closely scrutinised, and the authors of that study framed the work around low-dose co-administration rather than full doses of each agent (PMID 15833522).

Pigmentation and other melanocortin-related effects

Melanocortin agonists act on receptors that also influence pigmentation, and the 2026 therapeutic-peptide review discussed this receptor family in the context of aesthetic and endocrine applications alongside its safety summary (PMID 42123471). The short single-dose human PT-141 studies summarised above were not designed to detect changes that would require prolonged exposure, so that literature cannot speak to long-term dermatological outcomes.

Study-by-Study Snapshot

Refrigeration and Reconstitution: What the Literature Does and Does Not Report

Questions about whether PT-141 needs refrigeration, how long it lasts in the fridge and how long it remains good after reconstitution come up constantly — and the honest answer from the published record is that these are formulation and manufacturing questions, not clinical trial findings. The human studies summarised above reported pharmacokinetics, pharmacodynamics and adverse events; none of their abstracts reported a storage interval, a refrigerated shelf life or a post-reconstitution stability window (PMID 14999221, PMID 14963471).

Several points follow from that gap:

• Trial material was prepared under controlled conditions. Investigational nasal sprays and injectable solutions used in the 2004 and 2005 studies were supplied as finished study formulations, so participants were not handling stability decisions (PMID 15833522).
• Stability depends on the specific product. Peptide stability is a function of the exact salt form, excipients, pH, preservative system, container and concentration. A stability figure that applies to one manufacturer's lyophilised vial does not transfer to a different product, and none of the verified papers reported such figures.
• Research-use-only material is not labelled for human use. Vials sold for laboratory research typically carry the supplier's own handling documentation and a certificate of analysis. Those documents — not the clinical literature — are where storage claims for a given lot originate, and they are written for laboratory, not personal, contexts.
• Reviews emphasise unresolved practical questions. The 2025 narrative review on peptides for erectile dysfunction highlighted that formulation, delivery and standardisation remain open issues for this category of agents (PMID 40069591).

In short, anyone looking for "how long does PT-141 last in the refrigerator" or "how long is PT-141 good after reconstitution" in the peer-reviewed abstracts above will not find a number there, because those abstracts were not stability studies. Product-specific storage information belongs to a manufacturer's documentation or, for approved medicines, to regulator-approved labelling — and questions about the safety of any particular vial are ones for a licensed clinician or pharmacist rather than a literature summary.

Limits of the Safety Evidence

Three limitations recur across this body of work. First, the human PT-141 studies enrolled men and focused on erectile response endpoints, so the adverse-event profile they generated reflects that population and those measurement windows (PMID 14963471). Second, sample sizes in early-phase pharmacology work are small, which means uncommon events would not be expected to appear. Third, the two routes studied — intranasal and subcutaneous — were later developed differently, so adverse-event frequencies from one route are not interchangeable with the other (PMID 14999221).

Review articles add the wider caveat that peptide therapeutics vary enormously in how thoroughly they have been characterised, and that safety documentation is stronger for approved products than for compounds circulating as research chemicals (PMID 42123471).

Regulatory Context

Bremelanotide — the same molecule studied as PT-141 — was subsequently approved in the United States as a prescription injectable for hypoactive sexual desire disorder in premenopausal women, and that approved product carries regulator-reviewed labelling covering adverse reactions, contraindications and storage. Material sold as "PT-141" for research use only is not an approved medicine, is not dispensed with such labelling, and is not intended for human administration. These are regulatory facts rather than clinical recommendations, and nothing on this page is legal or medical advice.

Related Learning

This page is limited to adverse events, tolerability and the handling questions the literature leaves open. For the underlying pharmacology — melanocortin receptor subtypes, why the early programme tested two delivery routes, and how the trial endpoints were constructed — the structured PT-141 course walks through the same primary studies in teaching format rather than as a safety summary.

References

• Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra (International Journal of Impotence Research, 2004)
• Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction (International Journal of Impotence Research, 2004)
• Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response (Urology, 2005)
• Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions (Expert Opinion on Pharmacotherapy, 2025)
• Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives (International Journal of Molecular Sciences, 2026)